328 related articles for article (PubMed ID: 20337001)
21. Sugammadex rapidly reverses moderate rocuronium- or vecuronium-induced neuromuscular block during sevoflurane anaesthesia: a dose-response relationship.
Pühringer FK; Gordon M; Demeyer I; Sparr HJ; Ingimarsson J; Klarin B; van Duijnhoven W; Heeringa M
Br J Anaesth; 2010 Nov; 105(5):610-9. PubMed ID: 20876699
[TBL] [Abstract][Full Text] [Related]
22. [Pharmacology of sugammadex].
Meistelman C; Fuchs-Buder T
Ann Fr Anesth Reanim; 2009 Sep; 28 Suppl 2():S51-6. PubMed ID: 19887278
[TBL] [Abstract][Full Text] [Related]
23. Reversal of rocuronium-induced (1.2 mg/kg) profound neuromuscular block by sugammadex: a multicenter, dose-finding and safety study.
de Boer HD; Driessen JJ; Marcus MA; Kerkkamp H; Heeringa M; Klimek M
Anesthesiology; 2007 Aug; 107(2):239-44. PubMed ID: 17667567
[TBL] [Abstract][Full Text] [Related]
24. Sugammadex: a review of its use in anaesthetic practice.
Yang LP; Keam SJ
Drugs; 2009; 69(7):919-42. PubMed ID: 19441874
[TBL] [Abstract][Full Text] [Related]
25. Sugammadex efficacy for reversal of rocuronium- and vecuronium-induced neuromuscular blockade: A pooled analysis of 26 studies.
Herring WJ; Woo T; Assaid CA; Lupinacci RJ; Lemmens HJ; Blobner M; Khuenl-Brady KS
J Clin Anesth; 2017 Sep; 41():84-91. PubMed ID: 28802619
[TBL] [Abstract][Full Text] [Related]
26. Reversal of profound rocuronium or vecuronium-induced neuromuscular block with sugammadex in isoflurane-anaesthetised dogs.
Mosing M; Auer U; West E; Jones RS; Hunter JM
Vet J; 2012 Jun; 192(3):467-71. PubMed ID: 22030475
[TBL] [Abstract][Full Text] [Related]
27. [Sugammadex. New pharmacological concept for antagonizing rocuronium and vecuronium].
Sparr HJ; Booij LH; Fuchs-Buder T
Anaesthesist; 2009 Jan; 58(1):66-80. PubMed ID: 19082568
[TBL] [Abstract][Full Text] [Related]
28. Sugammadex: a cyclodextrin to reverse neuromuscular blockade in anaesthesia.
Donati F
Expert Opin Pharmacother; 2008 Jun; 9(8):1375-86. PubMed ID: 18473711
[TBL] [Abstract][Full Text] [Related]
29. Reversal of neuromuscular block with a selective relaxant-binding agent: sugammadex.
Ren WH; Jahr JS
Am J Ther; 2009; 16(4):295-9. PubMed ID: 19535969
[TBL] [Abstract][Full Text] [Related]
30. Sugammadex provides faster reversal of vecuronium-induced neuromuscular blockade compared with neostigmine: a multicenter, randomized, controlled trial.
Khuenl-Brady KS; Wattwil M; Vanacker BF; Lora-Tamayo JI; Rietbergen H; Alvarez-Gómez JA
Anesth Analg; 2010 Jan; 110(1):64-73. PubMed ID: 19713265
[TBL] [Abstract][Full Text] [Related]
31. An update on sugammadex sodium.
Welliver M; Cheek D
AANA J; 2009 Jun; 77(3):219-28. PubMed ID: 19645172
[TBL] [Abstract][Full Text] [Related]
32. Cochrane corner: sugammadex, a selective reversal medication for preventing postoperative residual neuromuscular blockade.
Abrishami A; Ho J; Wong J; Yin L; Chung F
Anesth Analg; 2010 Apr; 110(4):1239. PubMed ID: 20357160
[TBL] [Abstract][Full Text] [Related]
33. Reversal of rocuronium-induced neuromuscular block with sugammadex is faster than reversal of cisatracurium-induced block with neostigmine.
Flockton EA; Mastronardi P; Hunter JM; Gomar C; Mirakhur RK; Aguilera L; Giunta FG; Meistelman C; Prins ME
Br J Anaesth; 2008 May; 100(5):622-30. PubMed ID: 18385265
[TBL] [Abstract][Full Text] [Related]
34. A comparison of sugammadex and neostigmine for reversal of rocuronium-induced neuromuscular blockade in children.
Ammar AS; Mahmoud KM; Kasemy ZA
Acta Anaesthesiol Scand; 2017 Apr; 61(4):374-380. PubMed ID: 28185260
[TBL] [Abstract][Full Text] [Related]
35. Effects of sugammadex on incidence of postoperative residual neuromuscular blockade: a randomized, controlled study.
Brueckmann B; Sasaki N; Grobara P; Li MK; Woo T; de Bie J; Maktabi M; Lee J; Kwo J; Pino R; Sabouri AS; McGovern F; Staehr-Rye AK; Eikermann M
Br J Anaesth; 2015 Nov; 115(5):743-51. PubMed ID: 25935840
[TBL] [Abstract][Full Text] [Related]
36. Sugammadex approved to reverse NMBA effects.
Thompson CA
Am J Health Syst Pharm; 2016 Feb; 73(3):100. PubMed ID: 26796899
[No Abstract] [Full Text] [Related]
37. The use of sugammadex in a patient with myasthenia gravis.
Unterbuchner C; Fink H; Blobner M
Anaesthesia; 2010 Mar; 65(3):302-5. PubMed ID: 20105151
[TBL] [Abstract][Full Text] [Related]
38. Reversal with sugammadex in the absence of monitoring did not preclude residual neuromuscular block.
Kotake Y; Ochiai R; Suzuki T; Ogawa S; Takagi S; Ozaki M; Nakatsuka I; Takeda J
Anesth Analg; 2013 Aug; 117(2):345-51. PubMed ID: 23757472
[TBL] [Abstract][Full Text] [Related]
39. Sugammadex in anesthesia practice.
Duvaldestin P; Plaud B
Expert Opin Pharmacother; 2010 Nov; 11(16):2759-71. PubMed ID: 20977408
[TBL] [Abstract][Full Text] [Related]
40. Sugammadex: a selective relaxant-binding agent providing rapid reversal.
Rex C; Bergner UA; Pühringer FK
Curr Opin Anaesthesiol; 2010 Aug; 23(4):461-5. PubMed ID: 20489603
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
